Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Tatiana Kutateladze to Phosphatidylinositol 3-Kinases

This is a "connection" page, showing publications Tatiana Kutateladze has written about Phosphatidylinositol 3-Kinases.

 
Connection Strength
 
 
 
0.331
 
  1. Kutateladze TG. Mechanistic similarities in docking of the FYVE and PX domains to phosphatidylinositol 3-phosphate containing membranes. Prog Lipid Res. 2007 Nov; 46(6):315-27.
    View in: PubMed
    Score: 0.222
  2. Smith AL, Eiken AP, Skupa SA, Moore DY, Umeta LT, Smith LM, Lyden ER, D'Angelo CR, Kallam A, Vose JM, Kutateladze TG, El-Gamal D. A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia. Int J Mol Sci. 2022 Jun 16; 23(12).
    View in: PubMed
    Score: 0.039
  3. Acharya A, Pathania AS, Pandey K, Thurman M, Vann KR, Kutateladze TG, Challagundala KB, Durden DL, Byrareddy SN. PI3K-a/mTOR/BRD4 inhibitor alone or in combination with other anti-virals blocks replication of SARS-CoV-2 and its variants of concern including Delta and Omicron. Clin Transl Med. 2022 04; 12(4):e806.
    View in: PubMed
    Score: 0.038
  4. Kutateladze TG, Ogburn KD, Watson WT, de Beer T, Emr SD, Burd CG, Overduin M. Phosphatidylinositol 3-phosphate recognition by the FYVE domain. Mol Cell. 1999 Jun; 3(6):805-11.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)